Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
John Hornberger, Carolina Reyes, Ashwini Shewade, Susan Lerner, Mark Friedmann, Leona Han, Hialy Gutierrez, Sacha Satram-Hoang & Michael J. Keating. (2012) Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemia. Leukemia & Lymphoma 53:2, pages 225-234.
Read now
Read now
Charles L. Bennett, Denise Hynes, John Godwin, Tammy J. Stinson, Robert M. Golub & Frederick R. Appelbaum. (2001) Economic Analysis of Granulocyte Colony Stimulating Factor as Adjunct Therapy for Older Patients with Acute Myelogenous Leukemia (AML): Estimates from a Southwest Oncology Group Clinical Trial. Cancer Investigation 19:6, pages 603-610.
Read now
Read now
Charles L. Bennett & Tammy J. Stinson. (2000) Comparing Cost-Effectiveness Analyses for the Clinical Oncology Setting: The Example of the Gynecologic Oncology Group 111 Trial. Cancer Investigation 18:3, pages 261-268.
Read now
Read now
Articles from other publishers (26)
Arjun Gupta, Christopher J. O'Callaghan, Liting Zhu, Derek J. Jonker, Ralph P.W. Wong, Bruce Colwell, Malcolm J. Moore, Christos S. Karapetis, Niall C. Tebbutt, Jeremy D. Shapiro, Dongsheng Tu & Christopher M. Booth. (2023) Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial. JCO Oncology Practice 19:6, pages e859-e866.
Crossref
Crossref
Ann M. HendricksElizabeth Trice LoggersJames A. Talcott. (2011) Costs of Home Versus Inpatient Treatment for Fever and Neutropenia: Analysis of a Multicenter Randomized Trial. Journal of Clinical Oncology 29:30, pages 3984-3989.
Crossref
Crossref
Andre Konski, Mythreyi Bhargavan, Jean Owen, Rebecca Paulus, Jay Cooper, Arlene Forastiere, K. Kian Ang & Deborah Watkins-Bruner. (2011) Feasibility of Economic Analysis of Radiation Therapy Oncology Group (RTOG) 91-11 Using Medicare Data. International Journal of Radiation Oncology*Biology*Physics 79:2, pages 436-442.
Crossref
Crossref
Charles L. Bennett & Karen A. Fitzner. 2008. Abeloff's Clinical Oncology. Abeloff's Clinical Oncology
337
342
.
M. Hartmann, M. Fedders, A. Schneider, R. Kath, O. Camara & H. Oelschläger. (2007) Markov-modeling for the administration of platinum analogues and paclitaxel as first-line chemotherapy as well as topotecan and liposomal doxorubicin as second-line chemotherapy with epithelial ovarian carcinoma. Journal of Cancer Research and Clinical Oncology 133:9, pages 619-625.
Crossref
Crossref
Raymond NgBaktiar HasanNicole MittmannMarie FlorescuFrances A. ShepherdKeyue DingCharles Andrew ButtsYvon CormierGail DarlingGlenwood D. GossRichard InculetLesley SeymourTimothy L. WintonWilliam K. EvansNatasha B. Leighl. (2007) Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 25:16, pages 2256-2261.
Crossref
Crossref
Ann M. Mauer, Elizabeth S. Rich & Richard L. Schilsky. 2007. Cancer Clinical Trials: Proactive Strategies. Cancer Clinical Trials: Proactive Strategies
111
129
.
Johanna N.H. Timmer-Bonte, Eddy M.M. Adang, Hans J.M. Smit, Bonne Biesma, Frank A. Wilschut, Gerben P. Bootsma, Theo M. de Boo & Vivianne C.G. Tjan-Heijnen. (2006) Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer. Journal of Clinical Oncology 24:19, pages 2991-2997.
Crossref
Crossref
Takeshi Hara, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Yoshikawa, Naoe Goto, Yasushi Kojima, Toshiki Yamada, Michio Sawada, Takeshi Takahashi, Masami Oyama, Eiichi Tomita & Hisataka Moriwaki. (2005) Low-Dose Granulocyte Colony-Stimulating Factor Overcomes Neutropenia in the Treatment of Non-Hodgkin's Lymphoma with Higher Cost-Effectiveness. International Journal of Hematology 82:5, pages 430-436.
Crossref
Crossref
Bernie J. O'Brien. 2009. Outcomes Assessment in Cancer. Outcomes Assessment in Cancer
503
521
.
James J. Dignam. (2017) The Role of Cancer Cooperative Groups within the Spectrum of Cancer Care. Cancer Control 11:1, pages 55-63.
Crossref
Crossref
D.H. Smith, J.R. Adams, S.R.D. Johnston, A. Gordon, M.F. Drummond & C.L. Bennett. (2002) A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Annals of Oncology 13:10, pages 1590-1597.
Crossref
Crossref
Gary H. Lyman, Nicole M. Kuderer & Lodovico Balducci. (2002) Cost-benefit analysis of granulocyte colony-stimulating factor in the management of elderly cancer patients. Current Opinion in Hematology 9:3, pages 207-214.
Crossref
Crossref
Gary H. Lyman. (2001) Economic analysis of randomized, controlled trials. Current Oncology Reports 3:5, pages 396-403.
Crossref
Crossref
Howard OzerJames O. ArmitageCharles L. BennettJeffrey CrawfordGeorge D. DemetriPhilip A. PizzoCharles A. SchifferThomas J. SmithGeorge SomloJames C. WadeJames L. WadeIIIIIIRodger J. WinnAntoinette J. WozniakMark R. Somerfield. (2000) 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines. Journal of Clinical Oncology 18:20, pages 3558-3585.
Crossref
Crossref
Charles L. BennettTammy J. StinsonVictor VogelLyn RobertsonDonald LeedyPatrick O’BrienJane HobbsTamara SuttonJohn C. RuckdeschelThomas N. ChirikosRoy S. WeinerMarguerite M. RamseyMax S. Wicha. (2000) Evaluating the Financial Impact of Clinical Trials in Oncology: Results From a Pilot Study From the Association of American Cancer Institutes/Northwestern University Clinical Trials Costs and Charges Project. Journal of Clinical Oncology 18:15, pages 2805-2810.
Crossref
Crossref
JM Rowe. (2000) Treatment of acute myelogenous leukemia in older adults. Leukemia 14:3, pages 480-487.
Crossref
Crossref
Charles L. Bennett, Tammy J. Stinson, David Lane, Michael Amylon, Vita J. Land & Joseph H. Laver. (2000) Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: A case for prospective economic analysis in cooperative group trials. Medical and Pediatric Oncology 34:2, pages 92-96.
Crossref
Crossref
Gary H. Lyman & Lodovico Balducci. (1999) Update of the economic analyses of the use of the colony-stimulating factors. Current Opinion in Hematology 6:3, pages 145.
Crossref
Crossref
Viggo Jønsson, Mogen Mørk Hansen, Per Ljungman & Stein Kaasa. (2012) Pharmacoeconomic Considerations in Treating Patients With Acute Leukaemia. PharmacoEconomics 15:2, pages 167-178.
Crossref
Crossref
C.L. Bennett, T.J. Stinson, M.S. Tallman, E.A. Stadtmauer, R.W. Marsh, W. Friedenberg, H.M. Lazarus, L. Kaminer, R.M. Golub & J.M. Rowe. (1999) Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients ( > 55 to 70 years of age) with acute myelogenous leukemia. Annals of Oncology 10:2, pages 177-182.
Crossref
Crossref
Charles L. Bennett & Tammy J. Stinson. 1999. Clinical Applications of Cytokines and Growth Factors. Clinical Applications of Cytokines and Growth Factors
150
158
.
G.H Lyman, N Kuderer, J Greene & L Balducci. (1998) The economics of febrile neutropenia: implications for the use of colony-stimulating factors. European Journal of Cancer 34:12, pages 1857-1864.
Crossref
Crossref
Carole Rubino, Agne`s Laplanche, Catherine Patte & Jean Michon. (1998) Cost-Minimization Analysis of Prophylactic Granulocyte Colony-Stimulating Factor After Induction Chemotherapy in Children With Non-Hodgkin'ss Lymphoma. JNCI: Journal of the National Cancer Institute 90:10, pages 750-755.
Crossref
Crossref
Teresa M. Waters. 1998. Cancer Policy: Research and Methods. Cancer Policy: Research and Methods
25
36
.
Christopher E. Desch & Howard Ozer. (1997) Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy. Clinical Therapeutics 19:4, pages 847-865.
Crossref
Crossref